| Wissenschaftl. Titel | Clinical Trial of Nivolumab (BMS-936558) Combined With Ipilimumab Followed by Nivolumab Monotherapy as First-Line Therapy of Subjects With Histologically Confirmed Stage III (Unresectable) or Stage IV Melanoma CheckMate 401: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 401 |
| Erkrankung |
Haut:
Hautkrebs:
Schwarzer Hautkrebs (Malignes Melanom) - Erstlinie
|
| weitere Prüfzentren | |
| Kurzprotokoll | Kurzprotokoll |
erstellt 01.02.2017 Student Studienregister
geändert 16.08.2022 Student Studienregister